Cognitive-behavioral therapy, imipramine, or their corn or their combination for panic disorder: A randomized controlled trial

Journal of the American Medical Association

Volumn 283, Issue 19, 2000, Pages 2529-2536

  Barlow, David H ^a   Gorman, Jack M ^b,c   Shear, M Katherine ^e   Woods, Scott W ^f  

^a BOSTON UNIVERSITY   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE;

ADULT; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034679102     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.19.2529     Document Type: Article

References (48)

1. Keller MB, Yonkers KA, Warshaw, MG, et al. Remission and relapse in subjects with panic disorder and panic with agoraphobia, J Nerv Ment Dis. 1994;182: 290-296.
2. Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991.
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry. 1994; 51:8-19.
4. Sherbourne CD, Wells KB, Judd LL. Functioning and well-being of patients with panic disorder. Am J Psychiatry. 1996;153:213-218.
5. Klerman GL, Weissman MM, Ouellette R, et al. Panic attacks in the community. JAMA. 1991;265: 742-746.
6. Katon W. Primary care-psychiatry panic disorder management module. In: Wolfe BE, Maser JD, eds. Treatment of Panic Disorder: A Consensus Development Conference. Washington, DC: American Psychiatric Press Inc; 1994:4-56.
7. Beitman BD, Thomas AM, Kushner MG. Panic disorder in the families of patients with normal coronary arteries and non-fear panic disorder. Behav Res Ther. 1992;30:403-406.
8. Walker EA, Roy-Byrne PP, Katon WJ, et al. Psychiatric illness in irritable bowel syndrome. Am J Psychiatry. 1990;147:1656-1661.
9. Katerndahl DA, Realini JP. Where do panic attack sufferers seek care? J Fam Pract. 1995;40:237-243.
10. Swinson RP, Cox BJ, Woszczyna CB. Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. CMAJ. 1992;147:878.
11. Leon AC, Portera L, Weissman MM. The social costs of anxiety disorders. Br J Psychiatry Suppl. 1995; 166:19-22.
12. Salvador-Carulla L, Segui J, Fernandez-Cano P, Canet J. Costs and offset effect in panic disorders. Br J Psychiatry Suppl. 1995;166:23-28.
13. Hofmann S, Barlow DH. The costs of anxiety disorders. In: Miller NE, Magruder, KM eds. Cost-Effectiveness of Psychotherapy: A Guide for Practitioners, Researchers and Policymakers. New York, NY: Oxford University Press Inc; 1999:224-234.
14. Barlow DH, Craske MG, Cerny JA, Klosko JS. Behavioral treatment of panic disorder. Behav Ther. 1989; 20:261-282.
15. Clark DM, Salkovskis PM, Hackmann A, et al. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry. 1994;164:759-769.
16. Barlow DH, Lehman CL. Advances in the psychosocial treatment of anxiety disorders. Arch Gen Psychiatry. 1996;53:727-735.
17. Zitrin CM, Klein DF, Woerner MG. Treatment of agoraphobia with group exposure in vivo and imipramine Arch Gen Psychiatry. 1980;37:63-72.
18. Zitrin CM, Klein DF, Woerner MG, Ross DC, Treatment of phobias, I: comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry. 1983;40: 125-138.
19. Mavissakalian M, Michelson L. Two-year follow-up of exposure and imipramine treatment of agoraphobia. Am J Psychiatry. 1986;143:1106-1112.
20. Marks IM, Gray S, Cohen D, et al. Imipramine and brief therapist-aided exposure in agoraphobics having self-exposure homework. Arch Gen Psychiatry. 1983;40:153-162.
21. Mavissakalian MR, Perel JM. Imipramine treatment of panic disorder with agoraphobia. Am J Psychiatry. 1995;152:673-682.
22. Lydiard RB, Brawman-Mintzer O, Ballenger JC. Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol. 1996;64: 660-668.
23. Liebowitz MR, Barlow DH. Panic disorder: the latest on diagnosis and treatment. J Pract Psychiatry Behav Health. 1995;1:10-19.
24. Wolfe BE, Maser JD. Origins and overview of the consensus development conference on the treatment of panic disorder. In: Wolfe BE, Maser JD, eds. Treatment of Panic Disorder: A Consensus Development Conference. Washington, DC: American Psychiatric Press Inc; 1994:3-16.
25. Mavissakalian MR. Antidepressant medications for panic disorder. In: Mavissakalian MR, Prien RF, eds. Long-term Treatment of Anxiety Disorders. Washington, DC: American Psychiatric Press Inc; 1996:265.
26. Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry. 1993;50:44-50.
27. Marks IM, Swinson RP, Basoglu M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. Br J Psychiatry. 1993:162: 776-787.
28. Oehrburg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder. Br J Psychiatry. 1995;167:374-379.
29. Sharp DM, Power KG, Simpson RJ. Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia. J Anxiety Disord. 1996; 10:219-242.
30. Woods SW, Sholomskas DE, Shear MK, et al. Efficient allocation of patients to treatment cells in clinical trials with more than two treatment conditions. Am J Psychiatry. 1998;155:1446-1448.
31. Di Nardo PA, Barlow DH. Anxiety Disorders Interview Schedule-Revised: (ADIS-R). San Antonio, Tex: Graywind Publications Inc/The Psychological Corp; 1988.
32. Di Nardo PA, Moras K, Barlow DH, et al. Reliability of DSM-III-R anxiety disorder categories. Arch Gen Psychiatry. 1993;50:251-256.
33. Hofmann SG, Barlow DH, Papp LA, et al. Pretreatment attrition in a comparative treatment outcome study on panic disorder. Am J Psychiatry. 1998; 155:43-47.
34. Barlow DH, Craske MG. Mastery of Your Anxiety and Panic, II. San Antonio, Tex: Graywind Publications Inc/The Psychological Corp; 1994
35. Shear MK, Brown TA, Barlow DH, et al. Multi-center collaborative Panic Disorder Severity Scale. Am J Psychiatry. 1997;154:1571-1575.
36. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Washington, DC: US Government Printing Office; 1976. DHEW publication ADM 76-338.
37. Klein DF, Ross DC. Reanalysis of the National Institute of Mental Health Treatment of Depression Collaborative Research Program General Effectiveness Report. Neuropsychopharmacology. 1993;8:241-251.
38. Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants. Arch Gen Psychiatry. 1984;41:782-786.
39. Quitkin FM, Rabkin JD, Markowitz JM, et al. Use of pattern analysis to identify true drug response. Arch Gen Psychiatry. 1987;44:259-264.
40. Stewart JW, Quitkin FM, McGrath PJ, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry. 1998;55:334-343.
41. Lepola UM, Wade AG, Leinonen EV, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry. 1998; 59:528-534.
42. Telch MJ, Lucas JA, Schmidt NB, et al. Group cognitive-behavioral treatment of panic disorder. Behav Res Ther. 1993;31:279-287.
43. American Psychiatric Association, for the Work Group on Panic Disorder. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry. 1998;155(suppl 5):1-34.
44. Lecrubier Y, Bakker A, Dunbar G, Judge R, for The Collaborative Paroxetine Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand. 1997;95:145-152.
45. Bystritsky A, Rosen RM, Murphy KJ, et al. Double-blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety. 1994-1995;1:287-290.
46. Nair NP, Bakish D, Saxena B, et al. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety. 1996; 2:192-198.
47. Wade AG, Lepola U, Koponen HJ, et al. The effect of citalopram in panic disorder. Br J Psychiatry. 1997;170:549-553.
48. Uhlenhuth EH, Matuzas W, Warner TD, Thompson PM. Growing placebo response rate. Psychopharmacol Bull. 1997;33:31-39.